NCT00125099View on ClinicalTrials.gov

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2007

Conditions

HIV Infections

Interventions

BIOLOGICAL

VRC-HIVDNA009-00-VP

Trial Locations (5)

10021

Aaron Diamond AIDS Research Ctr. AIEDRP, New York

92103

Ucsd, Avrc Crs, San Diego

98104

UW Primary Infection Clinic CRS, Seattle

02114

Massachusetts General Hospital ACTG CRS, Boston

02115

Brigham and Women's Hosp. ACTG CRS, Boston

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00125099 - Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection | Biotech Hunter | Biotech Hunter